CBT-I vs sleeping pills: what the guidelines say

For chronic insomnia in adults, the American Academy of Sleep Medicine’s 2021 behavioral guideline gives a STRONG recommendation to multicomponent cognitive behavioral therapy for insomnia (CBT-I). The American College of Physicians said the same thing in 2016: start with CBT-I. Sleeping pills still have a defined role. Neither society wrote a slogan that CBT-I is simply “better than pills,” and a sleep-hygiene handout is not the treatment those documents describe.

What does the 2021 AASM guideline actually recommend?

Edinger and colleagues published the AASM clinical practice guideline in the February 2021 issue of the Journal of Clinical Sleep Medicine. The task force used GRADE. One recommendation is STRONG, meaning clinicians should follow it under most circumstances: use multicomponent CBT-I for chronic insomnia disorder in adults.

The same paper lists CONDITIONAL suggestions to use brief multicomponent therapies, or, as single-component treatments, stimulus control, sleep restriction therapy, or relaxation therapy. It also includes a CONDITIONAL suggestion that clinicians not use sleep hygiene as a single-component therapy for chronic insomnia in adults. Jack Edinger, the lead author, put that last point in plain language in the AASM news release: sleep hygiene practices are often suggested and well understood, but they do not constitute an effective stand-alone therapy.

Chronic insomnia, as the AASM summarized it with that guideline, is difficulty falling asleep, staying asleep, or waking earlier than wanted, despite enough time in bed, with daytime effects, at least three nights a week for at least three months. About 10 percent of adults meet that threshold in the AASM’s summary. If that description fits, you are past the point where a longer bedtime checklist is the indicated next step. The indicated behavioral treatment is CBT-I, not another round of “avoid screens and caffeine.”

CBT-I, in the AASM’s own definition, combines one or more cognitive strategies with education about sleep regulation plus behavioral strategies such as stimulus control and sleep restriction. Treatment typically involves four to eight sessions. That range is the guideline’s typical course, not a billing cap and not a program this office has published as its own.

What did ACP 2016 say about pills, and what did it not say?

The American College of Physicians’ 2016 guideline (Qaseem and colleagues, Annals of Internal Medicine) has two recommendations. Recommendation 1 is strong, based on moderate-quality evidence: all adult patients should receive CBT-I as the initial treatment for chronic insomnia disorder. Recommendation 2 is weak, based on low-quality evidence: if CBT-I alone was unsuccessful, clinicians should use shared decision-making, including a discussion of benefits, harms, and costs of short-term medication, to decide whether to add a drug.

ACP President Wayne Riley, in the College’s newsroom summary of that guideline, said something that marketing copy often drops: the evidence was insufficient to compare CBT-I and drug treatment directly. He added that CBT-I is likely to have fewer harms, and that sleep medications can be associated with serious adverse effects. That is the honest ceiling of the comparison. “CBT-I is better than pills” as a slogan goes past what ACP claimed. The College put CBT-I first because of benefit, likely milder harms, and the fact that skills can outlast a prescription. It did not rank named hypnotics against named CBT-I protocols in a head-to-head tournament.

ACP also noted that CBT-I can be delivered in person, in a group, by telephone, through web-based modules, or with self-help books, and that most of the trials it reviewed were in-person. Effectiveness of other formats was suggested by the data they had. That is still not a promise that a particular app is covered in Ohio or that a particular clinic runs one.

What actually happens in a typical four-to-eight-session course?

There is no single AASM-mandated session script. Standard protocols in the Bootzin and Perlis lineage, and in programs such as VA CBT-I, usually run weekly and include some version of the following. First, assessment and a sleep diary: insomnia history, comorbidities, one to two weeks of diary data, and a look for other sleep disorders that need medical treatment rather than a sleep-restriction window. Second, sleep restriction or sleep compression: a prescribed time-in-bed window close to average total sleep time, titrated from the diary using sleep efficiency. Third, stimulus control: bed for sleep and sex only; leave the bed if you are not sleeping; keep a consistent rise time; stop watching the clock. Fourth, cognitive work on unhelpful beliefs about sleep and on the daytime catastrophizing that keeps people in bed “just in case.” Relaxation or a wind-down is optional when hyperarousal is loud. Relapse planning is last: what to do after a bad night, and how to reopen the window without sliding back into eight empty hours in bed.

Sleep hygiene education is usually embedded in that course. It is not the course. If someone handed you a one-page list of bedroom rules and called it CBT-I, they used the wrong name. The 2021 guideline is explicit on that distinction, which is why this article is not a rewrite of sleep-hygiene advice. If you want the evidence on caffeine timing, late exercise, and naps, that is a different page.

A useful self-check before a visit is the Insomnia Severity Index. It is a questionnaire, not a diagnosis, and it does not replace an evaluation. Do not submit symptom detail through a website form. Bring the score to the appointment if you filled it out on paper.

When do the guidelines still discuss medication?

The AASM’s 2017 pharmacologic guideline, as the 2021 behavioral news release restated it, frames hypnotics mainly for patients who cannot participate in CBT-I, who still have symptoms after it, or who need a temporary adjunct. That is a sequence, not a ban. People with severe acute distress, no access to a CBT-I clinician, or a short window before a necessary trip can reasonably discuss a time-limited prescription. The 2017 document evaluated individual drugs on their own evidence. This article is not a drug-by-drug table. Named hypnotics, over-the-counter antihistamines, and melatonin products have mixed recommendations in that CPG; several over-the-counter agents are recommended against. If a medicine is on the table, it should be named in clinic against that document, not against a blog list.

In April 2026 the AASM published a separate guideline on combination treatment (Buysse and colleagues). Combination here means CBT-I started concurrently with a medication. Two CONDITIONAL recommendations, both low certainty: the Academy suggests combination over medication alone, and it suggests against combination over CBT-I alone. Daniel Buysse, the lead author, said in the AASM summary that CBT-I by itself is the most efficacious first-line treatment, and that adding a drug may give modest benefit for some outcomes, such as total sleep time, with added risk. Patients who want an early increase in time asleep and who accept medication exposure may reasonably choose combination. Others should get CBT-I alone. No specific hypnotic is preferred as the add-on in the AASM’s public summary of that CPG.

None of these documents say pills never work. None of them say CBT-I cures insomnia. The consistent instruction is: start with multicomponent CBT-I when it is available; use medicine as an adjunct or as an alternative when CBT-I is inaccessible or incomplete; revisit the drug rather than refilling it indefinitely without a plan.

Does Westerville Sleep Center deliver CBT-I?

That is unverified in the public materials for this practice. Do not assume Dr. Qadoom runs a six-week CBT-I clinic in Suite 230, and do not assume he does not refer. Ohio State Wexner Medical Center lists behavioral sleep medicine, including CBT-I, among its services in Columbus. Access exists in the metro. Whether this office delivers CBT-I in-house, by referral, or through a digital program is a question for the visit, not a claim to publish as fact.

A 2021 randomized trial by Arnedt and colleagues (60 adults with DSM-5 insomnia) compared six to eight weekly sessions by video telehealth with in-person CBT-I and with a waitlist. Insomnia Severity Index change at three months was −7.8 in person, −7.5 by telehealth, and −1.6 on the waitlist. Telehealth met the trial’s noninferiority margin of −3.0 ISI points. That is one small trial. It is not proof that every Ohio video visit is identical to every in-person course. It is relevant to access: if travel to a CBT-I clinician is the barrier, video is a studied option, not a rumor.

Insurance coverage of CBT-I is plan-specific. Billing often uses psychotherapy or health-behavior codes. Do not treat “many plans cover it” as a guarantee. Ask the insurer, or ask the office to help you check, before you count on a particular number of sessions.

What should you do if you have been managing insomnia with a nightly tablet?

Do not stop a prescribed hypnotic because a website ranked CBT-I first. Tapering is a clinical decision. Bring the bottle, the diary if you have one, and a clear account of how many nights a week you still sleep poorly. The evaluation for chronic insomnia also looks for obstructive sleep apnea, restless legs, circadian misalignment, pain, and mood disorders, because treating those can change what “insomnia” even is. CBT-I is first-line for chronic insomnia disorder. It is not a substitute for diagnosing something else that is fragmenting the night.

If the problem is chronic, the guidelines are aligned. Call (614) 898-9340 during weekday hours, or use the contact page, and ask for an appointment. The question to put on the table is not “which sleeping pill is strongest.” It is whether you have had a real CBT-I course, whether another sleep disorder needs testing first, and only then whether a short-term medicine belongs in the plan.